Form 4: Vanda Pharmaceuticals Director Anne Ward Receives Significant Equity Grant

Vanda Pharmaceuticals Inc. Director Anne Sempowski Ward was granted 59,225 shares of common stock in the form of a restricted stock unit (RSU) award, vesting fully on June 5, 2026.

Summary

• Anne Sempowski Ward, a Director of Vanda Pharmaceuticals Inc. (VNDA), acquired 59,225 shares of common stock on June 5, 2025.
• The acquisition was a grant of a time-based restricted stock unit (RSU) award, with a transaction price of $0 per share.
• Following this transaction, Ms. Ward beneficially owns a total of 119,067 shares of Vanda Pharmaceuticals common stock.
• The RSU award is set to vest 100% on June 5, 2026, contingent upon Ms. Ward providing continuous service to the Issuer through that date.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While it's a routine compensation event, it signifies continued alignment of a director's interests with shareholders and is a standard practice for corporate governance. There are no negative implications for the company's operations or financial health.

Positives

• The grant of restricted stock units to a director aligns their interests with those of long-term shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a common and effective way to incentivize directors to contribute to the company's success and growth.

Negatives

• The shares are subject to a vesting period, meaning the director does not have immediate full ownership or liquidity of the granted shares.
• While a non-cash transaction, RSU grants can lead to future share dilution upon vesting, though this is typically factored into compensation plans.

Risks

• The primary risk for the reporting person is the forfeiture of the RSU award if continuous service to Vanda Pharmaceuticals is not maintained until the vesting date of June 5, 2026.
• The ultimate value of the RSU award to the recipient is dependent on Vanda Pharmaceuticals' stock price at the time of vesting, introducing market risk.

Future Outlook

The future outlook for the granted RSUs is tied to the vesting schedule, with 100% of the shares expected to vest on June 5, 2026, provided the director maintains continuous service to the company.

Industry Context

The grant of restricted stock units to non-employee directors is a standard practice across various industries, including pharmaceuticals, as a form of equity compensation. It serves to attract and retain qualified board members and align their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a widely adopted practice among publicly traded companies, including those in the biotechnology and pharmaceutical sectors, such as Amgen Inc. (AMGN) or Gilead Sciences, Inc. (GILD), which frequently utilize equity awards to incentivize their board members.
• The vesting schedule, typically over one to three years, is also consistent with industry norms for time-based equity awards granted to directors, aiming to foster long-term commitment and stewardship.

Stakeholder Impact

• Shareholders: The grant of RSUs, while aligning director interests, will result in a minor increase in the number of outstanding shares upon vesting, leading to slight dilution.
• Director (Anne Sempowski Ward): Receives equity compensation, which provides a financial incentive tied to the company's stock performance and long-term value creation.

Next Steps

• The 59,225 restricted stock units are scheduled to vest on June 5, 2026, subject to the director's continuous service.

Key Dates

Keywords

Vanda Pharmaceuticals, VNDA, SEC Form 4, Insider Transaction, Restricted Stock Unit, RSU, Director Compensation, Equity Grant, Corporate Governance, Executive Compensation